Brokerages Set Kezar Life Sciences Inc (KZR) Price Target at $26.50

Shares of Kezar Life Sciences Inc (NASDAQ:KZR) have earned a consensus recommendation of “Buy” from the six ratings firms that are covering the firm, MarketBeat Ratings reports. Two analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $26.50.

A number of equities analysts recently issued reports on the stock. Zacks Investment Research lowered shares of Kezar Life Sciences from a “buy” rating to a “hold” rating in a research report on Wednesday, January 16th. William Blair reaffirmed an “outperform” rating on shares of Kezar Life Sciences in a research report on Tuesday, March 12th.

Hedge funds have recently made changes to their positions in the stock. New York State Common Retirement Fund bought a new position in Kezar Life Sciences during the fourth quarter worth $73,000. Slow Capital Inc. acquired a new stake in Kezar Life Sciences during the fourth quarter worth $216,000. Bank of New York Mellon Corp acquired a new stake in Kezar Life Sciences during the fourth quarter worth $411,000. Northern Trust Corp boosted its stake in Kezar Life Sciences by 8.7% during the fourth quarter. Northern Trust Corp now owns 56,993 shares of the company’s stock worth $1,345,000 after buying an additional 4,581 shares in the last quarter. Finally, Geode Capital Management LLC boosted its stake in Kezar Life Sciences by 126.7% during the fourth quarter. Geode Capital Management LLC now owns 58,046 shares of the company’s stock worth $1,369,000 after buying an additional 32,441 shares in the last quarter. 48.86% of the stock is currently owned by institutional investors and hedge funds.

Shares of NASDAQ:KZR traded down $0.77 during trading on Thursday, reaching $19.23. The stock had a trading volume of 25,176 shares, compared to its average volume of 65,519. Kezar Life Sciences has a 52 week low of $14.77 and a 52 week high of $36.33. The firm has a market cap of $367.64 million and a price-to-earnings ratio of -8.51.

Kezar Life Sciences (NASDAQ:KZR) last released its quarterly earnings results on Tuesday, March 26th. The company reported ($0.30) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.36) by $0.06. As a group, research analysts expect that Kezar Life Sciences will post -1.91 EPS for the current fiscal year.

About Kezar Life Sciences

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of small molecule therapeutics to treat unmet needs in autoimmunity and cancer in the United States. Its lead product candidate, KZR-616, a selective immunoproteasome inhibitor that is in Phase 1b/2 clinical trials in lupus and lupus nephritis The company was incorporated in 2015 and is headquartered in South San Francisco, California.

Recommended Story: Cost of Capital

Receive News & Ratings for Kezar Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kezar Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.